Hearst invests $75 million in Moffitt's M2Gen
M2Gen, a Moffitt Cancer Center subsidiary that uses big data to find ways to treat cancer, is receiving a $75 million equity investment from Hearst.
The partnership will help accelerate the discovery of innovative cancer therapies and improve care for patients nationwide, Hearst said in a press release.
The press release did not disclose the amount of the investment, but a Moffitt spokeswoman confirmed it was $75 million.
Hearst invests in c ompanies working to improve and advance health care,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Margie Manning Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Health Management | Partnerships